Maybe Obama Should Have Picked Welch, Not Immelt
|
|
Steve Jobs Leaves $11 Billion on the Table
|
|
Many CEOs Got to Start the Race Before Their Peers
|
|
Abercrombie Does Out-of-the-Money Options
|
|
It's Time To Deep-Six SERPs
|
|
Equilar's New S&P 500 Report
|
|
The Black-Scholes Model Seems to Overvalue Options
|
|
Equilar Releases Report on Consultants
|
|
The SEC Finally Gets It Right
|
|
The Impact of Option Timing
|
|
Burlington Northern: Warren Buffett's New Toy
|
|
Billionaires Are Good Buys for Shareholders
Equilar Releases New Study
Citigroup Grants Some Options
|
|
Equilar's New Peer Group Study
|
|
Stock Options Winners and Losers
|
|
$1 Million Pay Cap Portends Trouble for "Say on Pay"
|
|
There's More Pay-for-Performance Than We Think
|
|
What Has the Recession Done To Option Grants?
|
|
Equilar Releases Two New Studies
|
|
Health Insurers Don't Look Immoral to Me
|
|
Wall Street Needs an Extreme Pay Makeover
|
|
Equilar's New Benefits and Perquisites Study
|
|
More On the SEC's Proxy Proposals
|
|
A Mixed Bag of Reform Proposals From the SEC
|
|
Option Exchanges: OK or Immoral?
|
|
Dividend-Protected Stock Options May Be Good
|
|
Gilead's Martin: Super Performance, The Right Incentives
|
|
True Sacrifice: CEO Pay Rises 2% in 2008
|
|
Stock Options Are Not Intrinsically Evil
|
|
Obama's $500,000 Cap Feels Great, Does Nothing
|
|
The Endless Circle of Executive Pay
|
|
I'll Take It, Senator McCaskill!
|
|
A Different Way To Think About Stock Options
|
|
Stephen O'Byrne: A Serious Thinker About Compensation
|
|
Bye Bye, Shareownership Guidelines
|
|
There's Still a Case To Be Made For Stock Options
|
|
|
Opportunistically-Timed Options Are Alive and Well
|
|
Lee Iacocca Is Not a Good Role Model, Sen. Grassley
|
|
The Bureaucrats Take Over
|
|
In Bad Companies, Some Bonuses May Be Deserved
|
|
Option Certificates Morph to Wallpaper
|
|
|
Blending Different Option Types
|
|
Executive Pay Controls -- Bad Idea Then, Bad Idea Now
|
|
Pay for Chief Legal Officers
|
|
Pay in Computer and Software Companies -- $1.00 to $72 Million
|
|
Relative Total Return Plans Pose Serious Problems
|
|
The Largest Potential Option Gains
|
|
CEO: Worker Pay Ratios - It All Depends
|
|
Pharmaceutical Companies Pay Well - But In Line With Other Industries
|
|
|